logo
episode-header-image
Apr 2024
31m 37s

301: Biotech mega-rounds, a cancer vacci...

STAT
About this episode

Oruka Therapeutics CEO Lawrence Klein joins us to discuss how his company raised its first round of financing before competing with major players in the inflammation space. We also discuss the latest news in the life sciences, including the end of the Amylyx ALS saga, another use case for GLP-1s, and a hurdle in Verve’s gene editing plans. 

Here’s where you can subscribe to our biotech newsletter, The Readout. And here's where you can subscribe to our newsletter on the business (and secretive inner workings) of the U.S. health care industry, Health Care Inc.

Up next
Yesterday
360: NIH grant cuts, FDA transparency questions and biotech M&A
On this week’s episode of the Readout LOUD: A closer look at the NIH’s grant-cutting legal playbook, a not-so-transparent transparency push by the FDA commissioner, and another big biotech acquisition. Our colleague Anil Oza joins us to unravel a previously unseen memo he obtaine ... Show More
24m 18s
Jun 26
359: Vaccine policy frays, CDC nominee in the hot seat, & obesity drug side effects
We invite STAT’s senior writer for infectious diseases, Helen Branswell, and Washington correspondent Chelsea Cirruzzo on to the podcast to discuss the latest news at the CDC. The agency is in the spotlight once again, after the Senate grilled the potential head of the agency at ... Show More
34m 29s
Jun 19
358: FDA's gene therapy turmoil, and an alternative model for funding research
We discuss the tragic news that a second teenage boy with Duchenne muscular dystrophy died after taking Sarepta Therapeutics' gene therapy, raising renewed questions about the FDA's standards for approving drugs.We look at the continued turmoil within the FDA, including the force ... Show More
30m 12s
Recommended Episodes
Feb 2023
Healthspan, Lifespan, and the Biology of Aging
In this cross-over episode from Bio Eats World, Kristen Fortney, cofounder and CEO of BioAge, joins Vijay Pande, founding partner of a16z Bio + Health, and Olivia Webb, editorial lead, to discuss the biology of aging, how she started a company, and some fun things — like how long ... Show More
36m 45s
Apr 2024
The Deal Room: Alphabet Weighs Offer for HubSpot & 3 Hot M&A Breakdowns!
Join us this week in The Deal Room as we dissect the buzz surrounding Google's potential acquisition of HubSpot, a deal potentially valued at a $35bn. Discover the strategic reasoning behind it, potential synergies, and the looming antitrust hurdles. We also take you on a tour of ... Show More
43m 42s
Aug 2021
372: Biotech Billionaire Anne Wojcicki, Cofounder and CEO of 23andMe
You’ve heard data has the power to make or break a business. Nobody knows this more than Anne Wojcicki, co-founder of biotech giant 23andMe. After 15 years of leveraging data to build a game-changing company, Wojcicki made headlines this summer when she became the latest self-mad ... Show More
55m 20s
Jun 2023
The Successful Entrepreneur Formula w/ Salim Ismail | EP #47
In this episode, Peter and Salim take a deep dive into Exponential Organizations and how experimentation can help exponentially build a business.  You will learn about: 02:52 | The New School Is Surpassing The Old School. 18:50 | Trial & Error Will Give You The Data Necessary To ... Show More
34m 42s
Sep 2019
Transforming Health Insurance with Ali Diab, CEO of Collective Health
Ali Diab is the co-founder and CEO of Collective Health, a healthcare technology company that makes employee sponsored health insurance more transparent and simple to navigate. Ali was motivated to start Collective Health after his own medical event. As he was busy recovering fro ... Show More
58m 43s
Apr 2022
Spencer Health at Asembia 2022
Are you attending the #Asembia2022 Specialty Pharmacy Summit in Las Vegas? If so, then let's connect! The team will be on site and ready to show you how spencer can create a transformational experience for your patients. CLICK HERE: https://hubs.li/Q018_Mbp0 We talk with Mathew T ... Show More
22m 20s
Apr 2020
Gilead Virus Treatment Is Promising But No Silver Bullet Yet
Sam Fazeli, Director of Research: EMEA for Bloomberg Intelligence, on Gilead's positive trial for a potential coronavirus treatment. Lisa Shalett, Chief Investment Officer: Wealth Management for Morgan Stanley, discusses why she wants clients to avoid S&P indices and to actively ... Show More
30m 3s
Apr 2021
Virtual Reaity Robots Will Be Operating On You: Vicarious CEO
Adam Sachs, CEO and co-Founder of Vicarious Surgical, a robotic surgical company backed by Bill Gates, on using robotics technology and virtual reality to perform surgical procedures. Rick Palacios, Principal, Director of Research at John Burns Real Estate Consulting, on the inve ... Show More
26m 29s
Jan 2024
Big Pharma EXPOSED: Dr. John Abramson | PBD Podcast Ep. 351
John David Abramson is an American physician and the author of the book Overdosed America: The Broken Promise of American Medicine. He has worked as a family doctor in Appalachia and in Hamilton, Massachusetts, and has served as chairman of the department of family practice at La ... Show More
1h 33m